Real-world outcomes of first-line carboplatin–etoposide–atezolizumab in extensive-stage small-cell lung cancer
Aim: The addition of atezolizumab to platinum-etoposide chemotherapy has become the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, real-world data regarding treatment outcomes and prognostic factors remain limited. This study evaluated the effectiveness of first-line carbop...